Eli Lilly (LLY) PT Raised to $320 at BMO Capital on Longer-Term Margin Expansion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eli Lilly (LLY) PT Raised to $300 at BofA Securities
December 16, 2021 5:10 AM ESTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $300.00 (from $285.00) while maintaining a Buy rating.... More
Eli Lilly & Co. (LLY) Grinds Higher Following Outlook, Shares Up 8.6%
December 15, 2021 12:10 PM ESTEli Lilly & Co. (NYSE: LLY) pushes to session highs following strong guidance out earlier. Shares up 8.6%.
... MoreEli Lilly (LLY) Shares Soar on Raised FY21 Guidance, Analysts Positive
December 15, 2021 8:29 AM ESTShares of Eli Lilly (NYSE: LLY) are up about 5% in pre-open Wednesday after the company raised its full-year 2021 profit forecast on margin expansion.
Lilly said it now expects 2021 adjusted EPS to be between $8.15 and $8.20, up from an earlier range of between $7.95 and $8.05. Sales are seen between $28.0 billion to $28.3 billion, compared with its previous forecast of $27.2 billion to $27.6 billion.
"Lilly's accomplishments in recent years are impressive, but it's where we are going that most excites us. We've driven results over the last four... More
Lilly sees 2022 profit above estimates on boost from potential new drugs
December 15, 2021 7:13 AM ESTBy Mrinalika Roy
(Reuters) - Eli Lilly on Wednesday forecast 2022 profit above Wall Street estimates as it bets on new drug approvals to counter the impact of competition and pricing pressures on its other key treatments, sending its shares up nearly 10%.
The company has plans to launch five more medicines over the next two years, including diabetes drug tirzepatide and Alzheimer's disease treatment donanemab, helping it meets its target of launching 20 new... More
Eli Lilly (LLY) FY22 Guidances Tops Consensus
December 15, 2021 6:48 AM ESTEli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. At an investment community meeting today, the company is sharing key information across its four therapeutic areas including pipeline updates and future R&D investments along with 2022 financial guidance and updated 2021 guidance.
In today's presentations, Lilly will highlight newer medicines and upcoming launches expected to drive growth through the decade - showcasing how the company impacts millions of people and brings to life... More